Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Aging
Sirtris Pharmaceuticals In-Licenses Key Genetic Driver of Cellular Stress Resistance and Longevity in Mammals from Robarts Research Institute
March 28th, 2008
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced that it obtained exclusive, worldwide rights from Robarts Research Institute (London, Ontario, Canada) for NamPRT (also known as Visfatin), an important genetic driver of cellular stress resistance and longevity in mammals. The cellular longevity and stress resistance pathway in lower organisms is naturally triggered by the genetic switch PNC1. In mammals this process is evolutionarily conserved, and researchers have demonstrated that NamPRT serves the same role in mammalian...
Source: Health Business Week (2008-03-28)
|
